A Study of JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

About this Study

This is a non-randomized study looking at ruxolitinib in combination with a standard mult-agent chemotherapy regimen for the treatment of B-Acute Lymphoblastic Leukemia (B-ALL). 

Sponsor Protocol ID:AALL1521
IRB Number:2016-0212
Actively Enrolling
Interventional
Phase 2
May 28, 2019
Eligibility Criteria
Both Male and Female
Yes
Yes
No

Inclusion CriteriaNone

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Pediatrics
Participating Locations
Children's of Mississippi Center for Cancer and Blood Disorders
Children’s of Mississippi Hospital - Blair E. Batson Tower
Contact Information
Contact Name: Maggie Goad
Phone Number: 601-984-5220
Email: mgoad@umc.edu
Principal Investigator:Betty H. Melton
How to participate in our Clinical Trials